83 related articles for article (PubMed ID: 8479739)
1. Mutation of a phosphorylation site in the DNA-binding domain is required for redox-independent transactivation of AP1-dependent genes by v-Jun.
Oehler T; Pintzas A; Stumm S; Darling A; Gillespie D; Angel P
Oncogene; 1993 May; 8(5):1141-7. PubMed ID: 8479739
[TBL] [Abstract][Full Text] [Related]
2. Amino acid substitutions modulate the effect of Jun on transformation, transcriptional activation and DNA replication.
Morgan IM; Asano M; Håvarstein LS; Ishikawa H; Hiiragi T; Ito Y; Vogt PK
Oncogene; 1993 May; 8(5):1135-40. PubMed ID: 8479738
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional activation by the v-Jun oncoprotein is independent of positive regulatory phosphorylation.
Black EJ; Catling AD; Woodgett JR; Kilbey A; Gillespie DA
Oncogene; 1994 Aug; 9(8):2363-8. PubMed ID: 8036019
[TBL] [Abstract][Full Text] [Related]
4. Jun, the oncoprotein.
Vogt PK
Oncogene; 2001 Apr; 20(19):2365-77. PubMed ID: 11402333
[TBL] [Abstract][Full Text] [Related]
5. Directed mutation of the basic domain of v-Jun alters DNA binding specificity and abolishes its oncogenic activity in chicken embryo fibroblasts.
Basso J; Briggs J; Findlay C; Bos T
Oncogene; 2000 Oct; 19(42):4876-85. PubMed ID: 11039905
[TBL] [Abstract][Full Text] [Related]
6. Transactivation activity of Maf nuclear oncoprotein is modulated by Jun, Fos and small Maf proteins.
Kataoka K; Noda M; Nishizawa M
Oncogene; 1996 Jan; 12(1):53-62. PubMed ID: 8552399
[TBL] [Abstract][Full Text] [Related]
7. v-Rel and c-Rel are differentially affected by mutations at a consensus protein kinase recognition sequence.
Mosialos G; Gilmore TD
Oncogene; 1993 Mar; 8(3):721-30. PubMed ID: 8437855
[TBL] [Abstract][Full Text] [Related]
8. The defective transforming phenotype of c-Jun Ala(63/73) is rescued by mutation of the C-terminal phosphorylation site.
Bost F; Caron L; Vial E; Montreau N; Marchetti I; Dejong V; Defize L; Castellazzi M; Binétruy B
Oncogene; 2001 Nov; 20(50):7425-9. PubMed ID: 11704873
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional control of SPARC by v-Jun and other members of the AP1 family of transcription factors.
Vial E; Perez S; Castellazzi M
Oncogene; 2000 Oct; 19(43):5020-9. PubMed ID: 11042689
[TBL] [Abstract][Full Text] [Related]
10. The inhibitory activity of a transdominant c-jun mutant fused to the ligand binding domain of the estrogen receptor.
Kim S; Brown PH; Birrer MJ
Oncogene; 1996 Mar; 12(5):1043-53. PubMed ID: 8649795
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73.
Smeal T; Binetruy B; Mercola DA; Birrer M; Karin M
Nature; 1991 Dec; 354(6353):494-6. PubMed ID: 1749429
[TBL] [Abstract][Full Text] [Related]
12. Efficient induction of fibrosarcomas by v-jun requires mutations in the DNA binding region and the transactivation domain.
Morgan IM; Håvarstein LS; Wong WY; Luu P; Vogt PK
Oncogene; 1994 Oct; 9(10):2793-7. PubMed ID: 8084584
[TBL] [Abstract][Full Text] [Related]
13. The v-Jun oncoprotein replaces p39 c-Jun as the predominant AP-1 constituent in ASV17-transformed fibroblasts: implications for SAPK/JNK-mediated signal transduction.
Kilbey A; Black EJ; Unlu M; Gillespie DA
Oncogene; 1996 Jun; 12(11):2409-18. PubMed ID: 8649782
[TBL] [Abstract][Full Text] [Related]
14. Mitogenesis of quiescent chick fibroblasts by v-Src: dependence on events at the membrane leading to early changes in AP-1.
Catling AD; Wyke JA; Frame MC
Oncogene; 1993 Jul; 8(7):1875-86. PubMed ID: 8510932
[TBL] [Abstract][Full Text] [Related]
15. In vivo viral and cellular Jun complexes exhibit differential interaction with a number of in vitro generated 'AP-1- and CREB-like' target sequences.
Hadman M; Loo M; Bos TJ
Oncogene; 1993 Jul; 8(7):1895-903. PubMed ID: 8510933
[TBL] [Abstract][Full Text] [Related]
16. Jun and v-jun contain multiple regions that participate in transcriptional activation in an interdependent manner.
Angel P; Smeal T; Meek J; Karin M
New Biol; 1989 Oct; 1(1):35-43. PubMed ID: 2518690
[TBL] [Abstract][Full Text] [Related]
17. Differential and antagonistic effects of v-Jun and c-Jun.
Gao M; Morgan I; Vogt PK
Cancer Res; 1996 Sep; 56(18):4229-35. PubMed ID: 8797597
[TBL] [Abstract][Full Text] [Related]
18. TOJ3, a target of the v-Jun transcription factor, encodes a protein with transforming activity related to human microspherule protein 1 (MCRS1).
Bader AG; Schneider ML; Bister K; Hartl M
Oncogene; 2001 Nov; 20(51):7524-35. PubMed ID: 11709724
[TBL] [Abstract][Full Text] [Related]
19. Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes.
Li JJ; Rhim JS; Schlegel R; Vousden KH; Colburn NH
Oncogene; 1998 May; 16(21):2711-21. PubMed ID: 9652737
[TBL] [Abstract][Full Text] [Related]
20. v-Jun downregulates the SPARC target gene by binding to the proximal promoter indirectly through Sp1/3.
Chamboredon S; Briggs J; Vial E; Hurault J; Galvagni F; Oliviero S; Bos T; Castellazzi M
Oncogene; 2003 Jun; 22(26):4047-61. PubMed ID: 12821939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
